Novo post hoc analysis shows 25% weight loss in women on CagriSema
The REDEFINE 1 subgroup analysis spanned pre-, peri- and postmenopausal women, but roughly four in five trial participants reported digestive side effects.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 21 05:10 ETSource: Medical Daily
The wire
- 01Among 2,309 women in the 3,417-patient Phase 3 REDEFINE 1 trial, CagriSema produced 25.0% average weight loss at 68 weeks versus 19.0% for semaglutide alone, 13.4% for cagrilintide alone and 3% for placebo.
- 02The amylin-plus-GLP-1 combination gives clinicians comparative data by menopause stage: 26.7% premenopausal, 24.8% perimenopausal and 23.1% postmenopausal, with waist circumference down an average 20.5 cm.
- 03These are post hoc findings using the efficacy estimand, which assumes continued treatment; the broader trial measure showed 20.4%. CagriSema is unapproved, with an FDA decision expected in Q4 2026.
From the source
Read at medicaldaily.comWomen Lost 25% of Body Weight on CagriSema in Trial Analysis, but Most Users Had Digestive Side Effects
Women who took Novo Nordisk's experimental weight-loss injection CagriSema lost an average of 25% of their body weight over 68 weeks, according to a new analysis presented at The Menopause Society's 2026 annual meeting in San Diego and announced by Novo on October 20. Women on placebo lost 3%.
